Clearside Biomedical, Inc. (CLSD)
CLSD Stock Price Chart
Explore Clearside Biomedical, Inc. interactive price chart. Choose custom timeframes to analyze CLSD price movements and trends.
CLSD Company Profile
Discover essential business fundamentals and corporate details for Clearside Biomedical, Inc. (CLSD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
2 Jun 2016
Employees
32.00
Website
https://www.clearsidebio.comCEO
George M. Lasezkay Pharm.D., Pharma.D.
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.
CLSD Financial Timeline
Browse a chronological timeline of Clearside Biomedical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.07.
Earnings released on 8 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.12 by +50.00%, while revenue for the quarter reached $492.00K , beating expectations by +459.09%.
Earnings released on 14 May 2025
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $2.33M , beating expectations by +1.08K%.
Earnings released on 27 Mar 2025
EPS came in at -$0.10 surpassing the estimated -$0.13 by +23.08%, while revenue for the quarter reached $306.00K , beating expectations by +3.93%.
Earnings released on 12 Nov 2024
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $1.04M , beating expectations by +252.55%.
Earnings released on 12 Aug 2024
EPS came in at -$0.10 surpassing the estimated -$0.14 by +28.57%, while revenue for the quarter reached $90.00K , missing expectations by -40.00%.
Earnings released on 9 May 2024
EPS came in at -$0.17 falling short of the estimated -$0.14 by -21.43%, while revenue for the quarter reached $230.00K , missing expectations by -61.02%.
Earnings released on 12 Mar 2024
EPS came in at -$0.08 surpassing the estimated -$0.10 by +20.00%, while revenue for the quarter reached $6.35M , beating expectations by +43.23%.
Earnings released on 13 Nov 2023
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $859.00K , missing expectations by -76.53%.
Earnings released on 14 Aug 2023
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $1.02M , beating expectations by +748.33%.
Earnings released on 11 May 2023
EPS came in at -$0.15 falling short of the estimated -$0.14 by -7.14%, while revenue for the quarter reached $4.00K , missing expectations by -97.14%.
Earnings released on 9 Mar 2023
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%, while revenue for the quarter reached $330.00K , beating expectations by +230.00%.
Earnings released on 9 Nov 2022
EPS came in at -$0.13 falling short of the estimated -$0.03 by -282.35%, while revenue for the quarter reached $266.00K , missing expectations by -96.74%.
Earnings released on 9 Aug 2022
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $384.00K , beating expectations by +2.40%.
Earnings released on 11 May 2022
EPS came in at -$0.13 falling short of the estimated -$0.08 by -58.54%, while revenue for the quarter reached $347.00K , missing expectations by -95.34%.
Earnings released on 10 Mar 2022
EPS came in at $0.31 surpassing the estimated $0.16 by +93.75%, while revenue for the quarter reached $25.69M , beating expectations by +57.34%.
Earnings released on 10 Nov 2021
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%, while revenue for the quarter reached $3.07M , missing expectations by -10.00%.
Earnings released on 10 Aug 2021
EPS came in at -$0.11 surpassing the estimated -$0.12 by +8.33%, while revenue for the quarter reached $780.00K , meeting expectations.
Earnings released on 17 May 2021
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $34.00K , beating expectations by +42.86%.
Earnings released on 10 Mar 2021
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%, while revenue for the quarter reached $11.00K .
Earnings released on 10 Nov 2020
EPS came in at -$0.05 surpassing the estimated -$0.14 by +64.29%, while revenue for the quarter reached $3.43M , missing expectations by -29.82%.
CLSD Stock Performance
Access detailed CLSD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.